Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

45.34USD
17 Aug 2017
Change (% chg)

$-1.07 (-2.31%)
Prev Close
$46.41
Open
$45.38
Day's High
$45.82
Day's Low
$45.33
Volume
573,074
Avg. Vol
435,540
52-wk High
$47.97
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.61
Market Cap(Mil.): $90,360.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 0.47
Yield (%): 2.09

Financials

  NVO.N Industry Sector
P/E (TTM): 18.61 30.82 32.14
EPS (TTM): 2.43 -- --
ROI: 76.65 14.45 13.99
ROE: 84.84 15.54 15.33

Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

(This version of the story corrects paragraph 8 to remove reference to absorption of insulin)

17 Aug 2017

CORRECTED-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

17 Aug 2017

CORRECTED-Novo Nordisk's diabetes drug succeeds in key trial (Aug 16)

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

17 Aug 2017

UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial

Aug 16 Novo Nordisk A/S said on Wednesday its diabetes drug met the main goal of reducing glucose levels in patients in a key late-stage trial, setting the stage for it to become the new standard therapy for type 2 diabetes.

17 Aug 2017

BRIEF-Novo Nordisk says Semaglutide superior to Dulaglutide in sustain 7 trial

* Novo nordisk says semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in sustain 7

16 Aug 2017

BRIEF-‍Metacrine enters collaboration with Novo Nordisk to develop FGF 1 variants for glucose lowering, insulin sensitization​

* ‍Metacrine - entered collaboration with Novo Nordisk A/S to develop fibroblast growth factor 1 variants for glucose lowering and insulin sensitization​

15 Aug 2017

UPDATE 1-European shares fall on Paris incident, North Korea worries

* Overall euro zone Q2 earnings growth tracking 16 pct (Recasts, adds detail and quote, updates prices at close)

09 Aug 2017

UPDATE 2-Novo Nordisk raises forecasts despite continued U.S. pressure

* Shares jump more than 6 percent (Adds management comments, obesity drugs background, shares)

09 Aug 2017

BRIEF-Novo Nordisk CEO says won't provide explicit guidance on price

* CEO SAYS NOVO NORDISK DO NOT INTEND TO PROVIDE EXPLICIT GUIDANCE ON PRICE IN THE FUTURE

09 Aug 2017

NORDIC STOCKS - Factors to watch on August 9

OSLO, Aug 9 The following stocks may be affected by newspaper reports and other factors on Wednesday:

09 Aug 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €81.76 -1.00
Eli Lilly and Co (LLY.N) $77.80 -2.89

Earnings vs. Estimates